GO
Loading...

S&P Makes Index Changes After Spin-Offs

AP
Thursday, 21 Jun 2007 | 6:49 PM ET

Standard & Poor's made changes to several indexes due to Tyco International and Morgan Stanley spin-offs, and the inability of some companies to meet minimum market capitalization requirements.

After the close of trading June 29, S&P said medical device manufacturer Covidien will replace National Semiconductor in the S&P 100 and contract electronics maker Sanmina-SCI in the S&P 500.

  Price   Change %Change
DFS
---
PMCS
---
SANM
---
TYC
---

Meanwhile, Tyco Electronics will replace chip maker PMC-Sierra in the S&P 500 and the new Tyco International stock will replace the old ticker in the S&P 100 and 500.

The change comes after Tyco said it is spinning off Covidien and Tyco Electronics in a transaction expected to close June 29.

Sanmina-SCI and PMC-Sierra had market capitalizations that fell below the S&P 500 requirement for a minimum market capitalization of $4 billion.

S&P also said Discover Financial Services will replace networking equipment and software provider ADC Telecommunications in the S&P 500 and ADC will take PH Glatfelter's spot in the S&P MidCap 400.

S&P said it is making the switch because Morgan Stanley is spinning off Discover and PH Glatfelter did not meet the minimum $1 billion market capitalization rule for the S&P MidCap 400.

  Price   Change %Change
PMCS
---
SANM
---
TYC
---

Featured

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer discusses Micron Technology and how the company gained control over inventory issues. The bears expect the company's history to repeat itself, but Cramer says this time, it feels different.

  • In this excerpt from a live CNBC interview, Warren Buffett explains why it's extremely unusual for a company's directors to vote against executive compensation plans.

  • Mad Money host Jim Cramer says shareholder activism works for every shareholder, and offers his take on the Valeant/Bill Ackman bid to acquire Allergan. The market is better off for these efforts, he says.